Carcinomas, Hepatocellular
Conditions
Interventions
Case series:RFA
Sponsors
South Branch of Renji Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. For the first time were radical excision surgery, postoperative HCC diagnosed by pathological examination, cut edge negative, and residual liver left no residual carcinoma; 2. Liver function for the Child Pugh, grade A or B; 3. Confirmed by CT or MRI and other imaging examination for intrahepatic recurrence; 4. It is suitable for ablation treatment; 5. normal bone marrow reserve function in patients with line of ablation and normal liver kidney function.
Exclusion criteria
Exclusion criteria: 1. Clear distant metastasis of liver cancer or other malignant bile duct cell cancer of the liver; 2. had received radiation therapy for primary tumor or lymph node; 3. had received antitumor biological target therapy; 4. had received chemotherapy or immunotherapy for primary tumors; 5. Patients are being treated or had been treated with molecular targeted drugs such as sorafenib or TACE before operation; 6. Has serious coagulation dysfunction; 7. Combined with tumor thrombus from main portal vein to secondary branch, hepatic vein tumor thrombus, adjacent organ invasion or distant metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor cells;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Clinical benefit rate;Overall survival;Quality of life; | — |
Countries
China
Contacts
Public Contactjinhua jiang
South Branch of Renji Hospital, Shanghai JiaoTong University School of Medicine
Outcome results
None listed